This paper is based on mortality rate among older adults and individuals suffering from chronic diseases.It is critical to understand the molecular mechanisms by which COVID-19 affects the kidneys in order to develop appropriate nutritional and pharmacological strategies. Despite the fact that numerous studies have recently recommended various approaches for the management of COVID-19 in CKD, the impact on patients with renal diseases remains the greatest challenge globally.the most recent evidence on causality, potential nutritional supplements, therapeutic options, and management of COVID-19 infection in vulnerable individuals and CKD patients. To date, there is no effective treatment for COVID-19-induced kidney dysfunction, and current treatments are limited to anti-inflammatory (e.g., ibuprofen) and anti-viral medications (e.g., Remdesivir, and Chloroquine/Hydroxychloroquine) that may improve treatment chances. To summarise, we know very little about kidney damage in COVID-19, and this review improves our ability to introduce novel approaches for future clinical trials for this contiguous disease.
